The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so in that sense from a side effect profile we're really moving into a world where between perpendoic acid acetamide potentially obisetrapy and pcsk9 Inhibitors you're talking about a class of drugs that don't have side effects it's really the statins which obviously do have side effects although in relatively fewer people than is generally perceived that kind of give the overall class a bit of a bad name in terms of side effects
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.